Last updated on April 20, 2014 at 8:28 EDT

HAL Allergy Introduces Scientific Advisory Board

October 23, 2012

LEIDEN, The Netherlands, October 23, 2012 /PRNewswire/ –

HAL Allergy B.V. today introduces its Scientific Advisory Board. This group of
specialists will advise and assist the company in order to realize its future plans. The
successful kick-off meeting took place on October 6th in Leiden.

The introduction of the Scientific Advisory Board is an important step in the further
development of the organization. In 2011 HAL Allergy started an ambitious clinical
development program. The new scientific board will support the company in its ambitious
projects and will contribute to the future R & D program.

The expertise of the Scientific Advisory Board is vast:

        - Prof. Dr. Ronald van Ree - Professor of Molecular and Translational
          Allergology at Academic Medical Centre / University of Amsterdam. Also member of the
          Executive Committee EAACI and Chairman of the Scientific Advisory Board
        - Prof. Dr. Fatima Ferreira - Vice President for research at Salzburg
          University. Also Head of Christian Doppler Laboratory for Allergy Diagnosis and
        - Dr. Moises Calderon - Director Clinical Trials Unit at Imperial College,
          section of Allergy and Clinical Immunology. Also Chairman EAACI interest group
        - Dr. Oliver Pfaar - ENT Specialist at Centre for Rhinology and Allergology at
          the University Hospital Mannheim. Also Secretary EAACI interest group Immunotherapy

“We are proud at HAL Allergy to welcome this team of prominent scientists within the
field of allergy and immunotherapy,” says Harry Flore, CEO of the HAL Allergy Group.
“Their contribution and expertise will be of great value to our company. Their willingness
to be part of our Scientific Advisory Board underlines that we are on the right track to
realize our future goals and our innovative R & D program.”

About HAL Allergy

The HAL Allergy Group (http://www.hal-allergy.com) was established in 1959 and is
a main European manufacturer of allergy vaccines and diagnostics. The Group’s products are
distributed via subsidiaries in Germany, Spain, Italy, Poland, Austria and Benelux as well
as a network of distribution partners around Europe. Currently HAL Allergy employs over
280 people throughout Europe with more than 160 situated in the Netherlands HQ. The German
subsidiary in Duesseldorf has been in operation since 1977 and is one of the top three
players in the largest allergy market. It employs more than 60 people and is the main
sales and marketing operation for the HAL Allergy Group.


Source: PR Newswire